Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LASIX vs DEMADEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease including nephrotic syndrome,Hypertension (off-label)
Edema associated with heart failure, hepatic cirrhosis, and renal disease,Hypertension (off-label)
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (Cr Cl <20 m L/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 m L/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
Furosemide is metabolized primarily by glucuronidation via UGT1A1, with minimal hepatic metabolism; about 50% is excreted unchanged in urine.
Primarily hepatic via CYP450 enzymes, with minimal renal clearance.
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
91-99% bound, primarily to albumin.
Torsemide (DEMADEX) is extensively bound to plasma proteins, primarily albumin, with a protein binding of >99%.
0.1-0.2 L/kg in healthy adults; increases in conditions with reduced plasma protein binding (e.g., nephrotic syndrome) or fluid overload (e.g., heart failure) up to 0.3-0.8 L/kg.
The apparent volume of distribution (Vd) is approximately 0.16 L/kg (range 0.12–0.20 L/kg), indicating distribution primarily within extracellular fluid. Vd is increased in conditions with expanded extracellular volume (e.g., heart failure, cirrhosis, nephrotic syndrome).
Oral: 60-70% (range 50-80%); decreased by food; intravenous: 100%.
Oral bioavailability is approximately 80–90%, with minimal first-pass metabolism. Absorption is rapid and not significantly affected by food.
GFR 10-50 m L/min: dose every 12 hours; GFR <10 m L/min: avoid use or use with extreme caution.
GFR <20 m L/min/1.73 m²: Use with caution; may require dose reduction or discontinuation due to accumulation. GFR 20-50: No adjustment needed. GFR >50: No adjustment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or avoid.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval. Child-Pugh C: Avoid use or reduce dose by 75%.
1-2 mg/kg/dose PO or IV every 6-12 hours; maximum 6 mg/kg/day.
Neonates and infants: 0.1-0.2 mg/kg/dose IV/IM once daily. Children: Oral: 0.5-1 mg/kg once daily; IV/IM: 0.1-0.2 mg/kg/dose once daily. Maximum: 5 mg/day.
Start at 20 mg/day PO or 20 mg IV, titrate slowly due to increased sensitivity and risk of electrolyte disturbances.
Start at lower end of dose range (2.5-5 mg orally once daily); titrate slowly due to increased sensitivity and renal impairment risk.
Furosemide is a potent diuretic. If given in excessive amounts, it can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule must be adjusted to the individual patient's needs.
None.
Risk of hypovolemia, dehydration, and electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia, hypomagnesemia, hypocalcemia),Ototoxicity, especially with rapid injection or severe renal impairment,Sulfonamide cross-sensitivity
Hypotension and volume depletion,Electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia),Ototoxicity (especially with rapid IV administration or high doses),Hyperuricemia,Sulfonamide allergy cross-reactivity
Anuria,History of hypersensitivity to furosemide or sulfonamides
Anuria,Severe electrolyte depletion,Hypersensitivity to sulfonamides or bumetanide (Demadex is a sulfonamide derivative)
High sodium intake can counteract diuretic effects. Avoid excessive licorice consumption as it can worsen hypokalemia. Grapefruit juice may increase systemic exposure of furosemide; avoid concurrent use.
Avoid excessive licorice intake (glycyrrhizin) as it can exacerbate hypokalemia. Limit sodium-rich foods (processed foods, canned soups) to enhance diuretic effect and control edema. Increase potassium-rich foods (bananas, oranges, potatoes) unless on a potassium-sparing medication. Avoid grapefruit juice as it may affect metabolism.
Furosemide crosses the placenta. First trimester: limited data, no clear teratogenic pattern; risk cannot be excluded. Second and third trimesters: may cause maternal hypovolemia, decreased placental perfusion, electrolyte imbalances, and fetal dehydration; oligohydramnios reported. Use only if clearly needed.
DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human data; avoid unless benefit outweighs risk. Second/third trimester: risk of fetal oligohydramnios, renal impairment, and hypovolemia; use only if clearly needed.
Furosemide is excreted into breast milk in low amounts. M/P ratio approximately 1:1. No adverse effects reported in infants, but may suppress lactation. Use with caution, especially in neonates.
Torsemide is excreted in breast milk in small amounts; M/P ratio not reported. Due to potential for diuresis, electrolyte imbalance, and allergic reactions in the infant, caution is recommended. Alternative diuretics with more safety data are preferred.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing furosemide exposure. Dose adjustments may be necessary to maintain efficacy; titration based on clinical response and monitoring recommended. No established dose modification guidelines; individualize therapy.
Dosing may need adjustment due to increased plasma volume and GFR in pregnancy. Start at lowest effective dose. Monitor diuretic response and electrolyte balance; dose titration may be required. Postpartum, drug elimination may return to prepregnancy kinetics.
For rapid diuresis in acute pulmonary edema, administer IV furosemide slowly over 1-2 minutes to avoid ototoxicity. Monitor serum potassium closely, especially in patients on digoxin or with hepatic cirrhosis. Higher doses (>80 mg) may require divided doses to prevent peak-related adverse effects.
DEMADEX (torsemide) is a loop diuretic with high bioavailability (80-100%) and a longer half-life (3-4 hours) than furosemide, allowing once-daily dosing. It is primarily metabolized by CYP2C9, so caution is needed with CYP2C9 inhibitors like amiodarone. Monitor for ototoxicity at high doses or rapid infusion. Hypokalemia risk persists; consider potassium supplementation or aldosterone antagonist. Use cautiously in sulfonamide allergy due to potential cross-sensitivity.
Take furosemide exactly as prescribed, usually in the morning to avoid nighttime urination.,Weigh yourself daily and report rapid weight gain or loss of more than 2-3 pounds in a day.,Avoid prolonged sun exposure and use sunscreen as furosemide can increase sun sensitivity.,Do not stop taking this medication abruptly; tapering may be needed to avoid rebound fluid retention.
Take DEMADEX exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Weigh yourself daily and report sudden weight gain or loss of more than 2-3 pounds in a day.,Avoid alcohol and beverages containing caffeine as they may increase dehydration.,Do not take DEMADEX with licorice (which can worsen hypokalemia) or with high-sodium antacids.,Report signs of hearing loss, ringing in the ears, dizziness, or muscle cramps immediately.,Stand up slowly to prevent dizziness from low blood pressure.,Monitor for signs of dehydration: dry mouth, thirst, infrequent urination.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LASIX vs DEMADEX, answered by our medical review team.
LASIX is a Loop Diuretic that works by Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.. DEMADEX is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LASIX and DEMADEX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LASIX is: 20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.. The standard adult dose of DEMADEX is: Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LASIX and DEMADEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LASIX is classified as Category C. Furosemide crosses the placenta. First trimester: limited data, no clear teratogenic pattern; risk cannot be excluded. Second and third trimesters: may cause maternal hypovolemia, . DEMADEX is classified as Category C. DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human da. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.